声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。7月11日,药明康德(603259)发布2025年半年度业绩预增公告,营收207.99亿元同比增长20.64%、净利润63.15亿元,同比增长44.43%的亮眼数据,再次印证其全球CRDMO龙头的增长韧性。这组数据有多能打?放在医药圈里,活脱脱像班里那个...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.